Article Text
Letter
Adalimumab: a new modality for Behçet’s disease?
Statistics from Altmetric.com
Aberrant T cell function,1 subsequently accompanied by increased tumour necrosis factor α (TNFα) levels, induces inflammatory symptoms in patients with Behçet’s disease (BD).2 Subsequently, treatment usually involves T cell-directed immunosuppressive or anti-TNFα treatment in patients with severe disease.3–7 Administration of the new human monoclonal TNFα antibody adalimumab has only been described in three patients with BD with uveitis.8 We analysed the effects of adalimumab on severe and often chronic disease in six heavily pretreated patients with BD in whom immunosuppressive therapy had failed (table 1).
View this table:
- In this window
- In a new window
These patients were treated in the past with infliximab.9 Indications for anti-TNFα treatment …